LOC728379 Inhibitors
LOC728379 inhibitors encompass a diverse range of chemical compounds that effectively impede the functional activity of the protein through various biochemical mechanisms. For instance, protease inhibitors like E-64 and Leupeptin directly hinder the proteolytic functions that LOC728379 might participate in, assuming the protein possesses or interacts with cysteine or serine protease-like domains. Similarly, Pepstatin A would inhibit aspartic protease activity, thereby impeding any aspartate protease-mediated processes that LOC728379 could be involved in. Proteasome inhibitors such as MG132 and Lactacystin exert indirect effects by disrupting proteasomal degradation, leading to the possible accumulation and stabilization of proteins that can suppress LOC728379's activity through post-translational modifications.
Additionally, LOC728379's activity is conceivably regulated by various signal transduction pathways, and inhibitors that target these pathways can decrease its activity. PI3K inhibitors, LY294002 and PI-103, as well as mTOR inhibitor Rapamycin, have the capacity to disrupt the PI3K/AKT/mTOR axis, potentially leading to the downregulation of LOC728379 if the protein is linked to this pathway. MAPK pathwayinhibitors, such as U0126 and SB203580, mitigate the activation of ERK and p38 MAPK pathways, respectively, which could be crucial if LOC728379's function is modulated through these routes. The JNK inhibitor SP600125 further broadens the spectrum by targeting the JNK signaling pathway, offering another avenue for diminishing LOC728379's activity. Lastly, the tyrosine kinase inhibitor Dasatinib serves to inhibit key kinases within the cell, possibly affecting the functionality of LOC728379 if it is associated with kinase-driven signaling cascades.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
E-64 | 66701-25-5 | sc-201276 sc-201276A sc-201276B | 5 mg 25 mg 250 mg | $281.00 $947.00 $1574.00 | 14 | |
E-64 is a potent, irreversible cysteine protease inhibitor which could interfere with the proteolytic activity of LOC728379 if it has cysteine protease-like domains, thus inhibiting its functional enzymatic activity. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 is a proteasome inhibitor. By preventing proteasomal degradation, MG132 could lead to the accumulation of regulatory proteins that in turn might inhibit the activity of LOC728379 through post-translational modification. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
Lactacystin is another proteasome inhibitor that may have a similar effect to MG132, potentially inducing the accumulation of proteins that could suppress LOC728379's function by post-translational modification. | ||||||
Leupeptin hemisulfate | 103476-89-7 | sc-295358 sc-295358A sc-295358D sc-295358E sc-295358B sc-295358C | 5 mg 25 mg 50 mg 100 mg 500 mg 10 mg | $73.00 $148.00 $316.00 $499.00 $1427.00 $101.00 | 19 | |
Leupeptin is an inhibitor of serine and cysteine proteases, which may suppress the proteolytic cleavage that LOC728379 might be involved in, thus impeding its functional activity. | ||||||
PI-103 | 371935-74-9 | sc-203193 sc-203193A | 1 mg 5 mg | $33.00 $131.00 | 3 | |
PI-103 is a phosphoinositide 3-kinase inhibitor that could impede the PI3K/AKT/mTOR pathway, which might be indirectly involved in the regulation or activity of LOC728379. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another PI3K inhibitor that would affect the PI3K/AKT pathway, potentially causing downstream effects that result in the inactivity or reduced activity of LOC728379. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin selectively inhibits mTOR, which could disrupt signaling pathways that regulate the cell cycle and growth, potentially affecting LOC728379's function if it is related to these cellular processes. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a MEK inhibitor, which could prevent the activation of the MAPK/ERK pathway; if LOC728379 is regulated by or associated with this pathway, its inhibition could lead to the decreased functional activity of LOC728379. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor, which could suppress the p38 MAPK pathway and thus could interfere with the activity of LOC728379 if it is modulated by or involved in this signaling cascade. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which could lead to the suppression of the JNK signaling pathway. If LOC728379's activity is JNK-dependent, this inhibitor would decrease its functional activity. | ||||||